Early tests suggest that an antibody-based therapy is safe, with no harmful effects on healthy cells, suggesting that it ...

A key lung cancer congress held in Europe disclosed that a new breakthrough has been made by Hengrui Pharmaceuticals, a leading innovator in China’s pharmaceutical sector, to help prolong and improve ...

Mucormycosis, a life-threatening fungal infection with high mortality rates, has seen a glimmer of hope through research by ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...

Their paper, "A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response," was recently accepted and published in the Science Translational Medicine journal.

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution ...

Their paper, “A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response,” was recently accepted and published in the Science Translational Medicine journal.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...